Investors
SAN JOSE, Calif., Aug. 6, 2018 /PRNewswire/ -- Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections, today announced that it has launched an initial public offering of 2,000,000 shares of its common stock. In addition, Aridis has granted the underwriters a 30-day option to purchase up to 300,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares to be sold in the proposed offering will be offered by Aridis. The initial public offering price is expected to be between $13.00 and $15.00 per share. Aridis has applied to list the shares on the Nasdaq Capital Market under the symbol "ARDS."
Cantor Fitzgerald & Co. is acting as sole book-running manager for the offering. Maxim Group LLC is acting as lead manager and Laidlaw & Company (UK) Ltd., Northland Securities, Inc. and Seaport Global Securities LLC are acting as co-managers for the offering.
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
A registration statement relating to the offering has been filed with the Securities and Exchange Commission but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective.
The proposed offering will be made only by means of a prospectus. A copy of the preliminary prospectus may be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by e-mail at prospectus@cantor.com. The registration statement may be obtained free of charge at the SEC's website at www.sec.gov.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Contacts:
Tiberend Strategic Advisors, Inc.
Jonathon Brzezinski, Ph.D. (Investors)
(212) 375-2681
jbrzezinski@tiberend.com
David Schemelia (Media)
(212) 375-2686
dschemelia@tiberend.com
SOURCE Aridis Pharmaceuticals, Inc.